Corvus Pharmaceuticals CRVS Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's equity method investments?
- Corvus Pharmaceuticals (CRVS) reported equity method investments of $10.5M in Q1 2026.
- How has Corvus Pharmaceuticals's equity method investments changed year-over-year?
- Corvus Pharmaceuticals's equity method investments decreased by 13.0% year-over-year, from $12.06M to $10.5M.
- What is the long-term trend for Corvus Pharmaceuticals's equity method investments?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's equity method investments has grown at a -21.6% compound annual growth rate (CAGR), from $37.23M to $10.99M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.